AstraZeneca PLC annual gross profit for fiscal TTM was $49.4 billion, an increase of 2.6% from $48.1 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $49.4B | $48.1B | $43.9B | $37.5B | $32.0B | $25.0B | $21.3B | $19.5B | $17.2B | $18.1B | $18.9B | $20.1B | $20.7B | $20.5B | $22.6B | $27.6B | $26.9B | $27.0B | $25.0B | $23.1B | $20.9B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Gross Profit | $12.6B | $12.4B | $12.4B | $12.0B | $11.3B | $12.2B | $10.5B | $10.8B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More AZN metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All AZN financial statements → Interactive AZN charts →
About TickerBase · Data methodology & sources